S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Denali Therapeutics (DNLI) Short Interest Ratio & Short Volume

$16.00
-0.60 (-3.61%)
(As of 04/19/2024 ET)

Denali Therapeutics Short Interest Data

Current Short Volume
9,410,000 shares
Previous Short Volume
8,380,000 shares
Change Vs. Previous Month
+12.29%
Dollar Volume Sold Short
$193.09 million
Short Interest Ratio / Days to Cover
8.0
Last Record Date
March 31, 2024
Outstanding Shares
139,160,000 shares
Float Size
112,110,000 shares
Short Percent of Float
8.39%
Today's Trading Volume
1,479,992 shares
Average Trading Volume
944,577 shares
Today's Volume Vs. Average
157%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Denali Therapeutics ?

Sign up to receive the latest short interest report for Denali Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

DNLI Short Interest Over Time

DNLI Days to Cover Over Time

DNLI Percentage of Float Shorted Over Time

Denali Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/20249,410,000 shares $193.09 million +12.3%8.4%8 $20.52
3/15/20248,380,000 shares $168.69 million -5.5%7.5%7.2 $20.13
2/29/20248,870,000 shares $175.45 million -18.0%7.9%7.3 $19.78
2/15/202410,820,000 shares $198.66 million +10.0%9.7%9.5 $18.36
1/31/20249,840,000 shares $157.54 million -0.4%9.0%9.4 $16.01
1/15/20249,880,000 shares $183.18 million +2.6%8.7%9.5 $18.54
12/31/20239,630,000 shares $206.66 million +5.4%8.5%9.7 $21.46
12/15/20239,140,000 shares $209.67 million +0.2%8.0%9.2 $22.94
11/30/20239,120,000 shares $168.90 million -4.6%8.0%10.1 $18.52
11/15/20239,560,000 shares $176.67 million -10.9%8.4%11.2 $18.48
10/31/202310,730,000 shares $202.05 million +12.7%9.5%13.9 $18.83
10/15/20239,520,000 shares $197.64 million -2.0%8.8%13.7 $20.76
9/30/20239,710,000 shares $200.32 million +3.6%8.9%15.1 $20.63
9/15/20239,370,000 shares $220.66 million +3.1%8.6%15.4 $23.55
8/31/20239,090,000 shares $209.89 million -1.5%8.3%14 $23.09
8/15/20239,230,000 shares $224.20 million +6.2%8.5%13.9 $24.29
7/31/20238,690,000 shares $247.06 million +6.4%8.1%12.6 $28.43
7/15/20238,170,000 shares $239.63 million +1.4%7.7%11.4 $29.33
6/30/20238,060,000 shares $237.85 million -7.7%7.5%10.5 $29.51
6/15/20238,730,000 shares $283.64 million +8.0%8.2%11.1 $32.49
5/31/20238,080,000 shares $244.18 million -6.4%7.6%10.8 $30.22
5/15/20238,630,000 shares $276.33 million No Change8.1%11.4 $32.02
10/31/20226,980,000 shares $200.19 million -4.3%6.2%8.4 $28.68
10/15/20227,290,000 shares $237.44 million +2.7%6.6%9 $32.57
9/30/20227,100,000 shares $217.90 million +6.6%7.0%10.5 $30.69
9/15/20226,660,000 shares $207.06 million +0.2%6.5%10.5 $31.09
8/31/20226,650,000 shares $184.01 million +2.0%6.5%9.9 $27.67
8/15/20226,520,000 shares $245.22 million -11.5%6.4%10.4 $37.61
7/31/20227,370,000 shares $250.73 million -2.5%7.6%11.2 $34.02
7/15/20227,560,000 shares $262.33 million -0.4%7.8%12 $34.70
6/30/20227,590,000 shares $223.37 million -3.2%7.8%12.5 $29.43
6/15/20227,840,000 shares $177.03 million +0.5%8.1%13.4 $22.58
5/31/20227,800,000 shares $189.46 million +5.4%8.0%14.7 $24.29
5/15/20227,400,000 shares $169.16 million +11.1%7.6%13.7 $22.86
4/30/20226,660,000 shares $158.51 million +1.1%6.9%12.8 $23.80
4/15/20226,590,000 shares $198.42 million -2.2%6.8%12.9 $30.11
3/31/20226,740,000 shares $216.83 million +0.2%N/A11.5 $32.17
3/15/20226,730,000 shares $199.28 million +3.5%6.9%11.5 $29.61
2/28/20226,500,000 shares $211.64 million -2.1%7.8%11.1 $32.56
2/15/20226,640,000 shares $236.65 million +20.7%8.0%11.3 $35.64
A.I. Pioneer Issues Urgent Warning to Americans (Ad)

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

DNLI Short Interest - Frequently Asked Questions

What is Denali Therapeutics' current short interest?

Short interest is the volume of Denali Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 9,410,000 shares of DNLI short. 8.39% of Denali Therapeutics' shares are currently sold short. Learn More on Denali Therapeutics' current short interest.

What is a good short interest ratio for Denali Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNLI shares currently have a short interest ratio of 8.0. Learn More on Denali Therapeutics's short interest ratio.

Which institutional investors are shorting Denali Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Denali Therapeutics: Barclays PLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Denali Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.39% of Denali Therapeutics' floating shares are currently sold short.

Is Denali Therapeutics' short interest increasing or decreasing?

Denali Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 12.3% from the previous total of 8,380,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Denali Therapeutics' float size?

Denali Therapeutics currently has issued a total of 139,160,000 shares. Some of Denali Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Denali Therapeutics currently has a public float of 112,110,000 shares.

How does Denali Therapeutics' short interest compare to its competitors?

8.39% of Denali Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Denali Therapeutics: Vericel Co. (9.07%), Immunocore Holdings plc (9.49%), Beam Therapeutics Inc. (16.47%), Kymera Therapeutics, Inc. (14.83%), Ginkgo Bioworks Holdings, Inc. (20.21%), Arcellx, Inc. (9.85%), Apogee Therapeutics, Inc. (13.11%), Sana Biotechnology, Inc. (22.16%), Fusion Pharmaceuticals Inc. (6.13%), Recursion Pharmaceuticals, Inc. (27.13%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Denali Therapeutics stock?

Short selling DNLI is an investing strategy that aims to generate trading profit from Denali Therapeutics as its price is falling. DNLI shares are trading down $0.60 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Denali Therapeutics?

A short squeeze for Denali Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNLI, which in turn drives the price of the stock up even further.

How often is Denali Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNLI, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:DNLI) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners